Pharmaceuticals company Zydus Lifesciences announced Q1FY26 results Revenue from Operations was Rs 65,737 million, up 6% YoY. Research & Development (R&D;) investments for the quarter stood at Rs 4,856 million (7.4% of revenue). EBITDA for the quarter was Rs 20,885 million, flat YoY. EBITDA margin for the quarter stood at 31.8%. Net Profit for the quarter was Rs 14,668 million, up 3% YoY. Capex (organic) for the quarter was Rs 4,020 million. Sharvil Patel, Managing Director, Zydus Lifesciences, said, "Our Q1FY26 performance reflects the results of our disciplined execution, with most of our key businesses meeting expectations. We remain firmly on track to achieve our FY26 aspirations and are excited about the upcoming developments on the innovation front, which we believe will open up new avenues for sustainable growth. As we pursue these opportunities, we continue to keep the highest standards of compliance at the core of all our operations, while building strong future growth pillars that will strengthen our position globally". Result PDF
Pharmaceuticals company Zydus Lifesciences announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue from operations at Rs 65,279 million, up 18% over last year. Research & Development (R&D;) investments for the quarter stood at Rs 4,799 million (7.4% of revenues). EBITDA for the quarter was Rs 21,255 million, up 30% YoY. EBITDA margin for the quarter stood at 32.6%, which is an improvement of 310 bps on a YoY basis. Net Profit, adjusted for exceptional items, was Rs 13,905 million, up 18% YoY. Capex (organic) for the quarter was Rs 3,202 million. FY25 Financial Highlights: Revenue from operations at Rs 2,32,415 million, up 19% over last year. • Research & Development (R&D;) investments for the year stood at Rs 18,555 million (8.0% of revenues). EBITDA for the year was Rs 70,585 million, up 31% YoY. EBITDA margin for the year stood at 30.4%, which is an improvement of 290 bps over the previous year. Net Profit, adjusted for exceptional items, was Rs 47,451 million, up 23% YoY. Capex (organic) for the full year was Rs 12,140 million. Net Debt to Equity ratio as on 31st March, 2025 was -0.20x while Net Debt to EBITDA stood at -0.69x at the end of March, 2025. Net Cash (negative Net Debt) as on March 31st, 2025 was Rs 48,836 million. Sharvil Patel, Managing Director - Zydus Lifesciences said, "We are happy to conclude FY 2025 on a strong note, with all our businesses surpassing our growth expectations. The commercial success of our extensive product portfolio combined with operating leverage has significantly bolstered profitability and financial health. We made meaningful progress in our differentiated pipeline and added new capabilities to ensure sustainable growth. We look forward to continued execution success and deepening strategic partnerships to drive long term growth. Our commitment to maintaining the highest quality standards across our operations remains unwavering.” Result PDF